clofibric acid

Summary

Summary: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.

Top Publications

  1. Marco Urrea E, Radjenovic J, Caminal G, Petrovic M, Vicent T, Barcelo D. Oxidation of atenolol, propranolol, carbamazepine and clofibric acid by a biological Fenton-like system mediated by the white-rot fungus Trametes versicolor. Water Res. 2010;44:521-32 pubmed publisher
    Biological advanced oxidation of the pharmaceuticals clofibric acid (CA), carbamazepine (CBZP), atenolol (ATL) and propranolol (PPL) is reported for the first time...
  2. Nunes B, Carvalho F, Guilhermino L. Acute and chronic effects of clofibrate and clofibric acid on the enzymes acetylcholinesterase, lactate dehydrogenase and catalase of the mosquitofish, Gambusia holbrooki. Chemosphere. 2004;57:1581-9 pubmed
    The objective of this study was to investigate both acute and chronic effects of clofibrate and clofibric acid on the enzymes acetylcholinesterase (AChE), lactate dehydrogenase (LDH) and catalase (CAT) of the mosquitofish (Gambusia ..
  3. Weston A, Caminada D, Galicia H, Fent K. Effects of lipid-lowering pharmaceuticals bezafibrate and clofibric acid on lipid metabolism in fathead minnow (Pimephales promelas). Environ Toxicol Chem. 2009;28:2648-55 pubmed publisher
    The lipid-lowering agents bezafibrate and clofibric acid, which occur at concentrations up to 3.1 and 1.6 microg/L, respectively, are among the most frequently found human pharmaceuticals in the aquatic environment...
  4. Peffer P, Lin X, Odle J. Hepatic beta-oxidation and carnitine palmitoyltransferase I in neonatal pigs after dietary treatments of clofibric acid, isoproterenol, and medium-chain triglycerides. Am J Physiol Regul Integr Comp Physiol. 2005;288:R1518-24 pubmed
    ..The long-chain control diet was supplemented further with clofibric acid (0.5%) or isoproterenol (40 ppm), and growth was monitored for 10-12 days...
  5. Birjmohun R, Hutten B, Kastelein J, Stroes E. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005;45:185-97 pubmed
    ..The aim of this research was to estimate the efficacy and safety of current high-density lipoprotein cholesterol (HDL-C)-increasing drugs...
  6. Studer M, Briel M, Leimenstoll B, Glass T, Bucher H. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med. 2005;165:725-30 pubmed
    ..Mortality data are the most reliable data to assess efficacy of interventions. We aimed to assess efficacy and safety of different lipid-lowering interventions based on mortality data...
  7. Despres J, Lemieux I, Robins S. Role of fibric acid derivatives in the management of risk factors for coronary heart disease. Drugs. 2004;64:2177-98 pubmed
  8. Michel C, Desdouets C, Sacre Salem B, Gautier J, Roberts R, Boitier E. Liver gene expression profiles of rats treated with clofibric acid: comparison of whole liver and laser capture microdissected liver. Am J Pathol. 2003;163:2191-9 pubmed
    b>Clofibric acid (CLO) is a peroxisome proliferator (PP) that acts through the peroxisome proliferator activated receptor alpha, leading to hepatocarcinogenesis in rodents...
  9. Yokoyama Y, Xin B, Shigeto T, Umemoto M, Kasai Sakamoto A, Futagami M, et al. Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer. Mol Cancer Ther. 2007;6:1379-86 pubmed
    ..In this study, we investigated the inhibitory effect of clofibric acid (CA), a ligand for PPARalpha on growth of ovarian malignancy, in in vivo and in vitro experiments using OVCAR-..

More Information

Publications62

  1. Robins S, Bloomfield H. Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials. Curr Opin Lipidol. 2006;17:431-9 pubmed
    ..This review focuses on a number of extended analyses from these trials that may relate to the success or failure of fibrate therapy and indicate who might likely benefit from this therapy...
  2. Emblidge J, DeLorenzo M. Preliminary risk assessment of the lipid-regulating pharmaceutical clofibric acid, for three estuarine species. Environ Res. 2006;100:216-26 pubmed
    b>Clofibric acid is the active metabolite of several fibrate drugs prescribed to reduce blood cholesterol levels. It is persistent and widely detected in the environment...
  3. Ammazzalorso A, Amoroso R, Baraldi M, Bettoni G, Braghiroli D, De Filippis B, et al. Synthesis and antiplatelet activity of thioaryloxyacids analogues of clofibric acid. Eur J Med Chem. 2005;40:918-21 pubmed
    The thiophene-, benzothiazole- and pyridine-thioaryloxyacids analogues of clofibric acid were synthesized and their antiplatelet activity was screened. Some compounds exhibited antiaggregating properties...
  4. Verges B. Role for fibrate therapy in diabetes: evidence before FIELD. Curr Opin Lipidol. 2005;16:648-51 pubmed
    ..Statins have been shown to diminish significantly the risk for coronary disease in patients with type 2 diabetes, and so what are the real effects of fibrates on cardiovascular risk in type 2 diabetes?..
  5. Graham D, Staffa J, Shatin D, Andrade S, Schech S, La Grenade L, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292:2585-90 pubmed
    ..Lipid-lowering agents are widely prescribed in the United States. Reliable estimates of rhabdomyolysis risk with various lipid-lowering agents are not available...
  6. Andreozzi R, Caprio V, Marotta R, Radovnikovic A. Ozonation and H2O2/UV treatment of clofibric acid in water: a kinetic investigation. J Hazard Mater. 2003;103:233-46 pubmed
    ..The present work aims at assessing the kinetics of abatement from aqueous solutions of clofibric acid (a metabolite of the blood lipid regulator clofibrate) which has been found in surface, ground and drinking ..
  7. Staels B, Fruchart J. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes. 2005;54:2460-70 pubmed
    ..The functions of a third PPAR isoform, PPARdelta, and its potential as a therapeutic target are currently under investigation...
  8. Triebskorn R, Casper H, Scheil V, Schwaiger J. Ultrastructural effects of pharmaceuticals (carbamazepine, clofibric acid, metoprolol, diclofenac) in rainbow trout (Oncorhynchus mykiss) and common carp (Cyprinus carpio). Anal Bioanal Chem. 2007;387:1405-16 pubmed
    ..of human pharmaceuticals in aquatic wildlife, laboratory experiments were conducted with carbamazepine, clofibric acid, metoprolol, and diclofenac using fish as test organisms...
  9. Kourimate S, Le May C, Langhi C, Jarnoux A, Ouguerram K, Zair Y, et al. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9. J Biol Chem. 2008;283:9666-73 pubmed publisher
    ..Moreover, this study validates the functional relevance of a combined therapy associating PCSK9 repressors and statins...
  10. Richert L, Lamboley C, Viollon Abadie C, Grass P, Hartmann N, Laurent S, et al. Effects of clofibric acid on mRNA expression profiles in primary cultures of rat, mouse and human hepatocytes. Toxicol Appl Pharmacol. 2003;191:130-46 pubmed
    The mRNA expression profile in control and clofibric acid (CLO)-treated mouse, rat, and human hepatocytes was analyzed using species-specific oligonucleotide DNA microarrays (Affymetrix)...
  11. Robins S. Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?. Curr Opin Lipidol. 2003;14:575-83 pubmed
  12. Runnalls T, Hala D, Sumpter J. Preliminary studies into the effects of the human pharmaceutical Clofibric acid on sperm parameters in adult Fathead minnow. Aquat Toxicol. 2007;84:111-8 pubmed
    The effects of Clofibric acid (a persistent environmental metabolite of Clofibrate, a human pharmaceutical), on Fathead minnows were studied. Fibrates are used to prevent cardiovascular disease through their antilipidemic activity...
  13. Brunzell J. Clinical practice. Hypertriglyceridemia. N Engl J Med. 2007;357:1009-17 pubmed
  14. Giampietro L, Ammazzalorso A, Giancristofaro A, Lannutti F, Bettoni G, De Filippis B, et al. Synthesis and biological evaluation of 2-heteroarylthioalkanoic acid analogues of clofibric acid as peroxisome proliferator-activated receptor alpha agonists. J Med Chem. 2009;52:6224-32 pubmed publisher
    A series of 2-heteroarylthioalkanoic acids were synthesized through systematic structural modifications of clofibric acid and evaluated for human peroxisome proliferator-activated receptor alpha (PPARalpha) transactivation activity, with ..
  15. Owen S, Huggett D, Hutchinson T, Hetheridge M, McCormack P, Kinter L, et al. The value of repeating studies and multiple controls: replicated 28-day growth studies of rainbow trout exposed to clofibric acid. Environ Toxicol Chem. 2010;29:2831-9 pubmed publisher
    Two studies to examine the effect of waterborne clofibric acid (CA) on growth-rate and condition of rainbow trout were conducted using accepted regulatory tests (Organisation for Economic Co-operation and Development [OECD] 215)...
  16. Hwang B, Wu P, Harris R. Additive effects of clofibric acid and pyruvate dehydrogenase kinase isoenzyme 4 (PDK4) deficiency on hepatic steatosis in mice fed a high saturated fat diet. FEBS J. 2012;279:1883-93 pubmed publisher
    ..In the present study, the effects of clofibric acid, a PPAR? agonist, on blood and liver lipids were determined in wild-type and PDK4 knockout mice fed a high-fat ..
  17. Gao Y, Deshusses M. Adsorption of clofibric acid and ketoprofen onto powdered activated carbon: effect of natural organic matter. Environ Technol. 2011;33:1719-27 pubmed
    The adsorption of two acidic pharmaceutically active compounds (PhACs), clofibric acid and ketoprofen, onto powdered activated carbon (PAC) was investigated with a particular focus on the influence of natural organic matter (NOM) on the ..
  18. Backes J, Gibson C. Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein. Ann Pharmacother. 2005;39:523-6 pubmed
    ..To review the effects of lipid-lowering therapy on small-dense low-density lipoprotein cholesterol (sdLDL-C)...
  19. Barrass N, Price R, Lake B, Orton T. Comparison of the acute and chronic mitogenic effects of the peroxisome proliferators methylclofenapate and clofibric acid in rat liver. Carcinogenesis. 1993;14:1451-6 pubmed
    ..of acute (1 week) and chronic (26 week) exposure to the peroxisome proliferators methylclofenapate (MCP) and clofibric acid (CA), at 0.05 and 0.5% in the diet respectively, on hepatocyte replication in the Sprague-Dawley rat...
  20. Kobayashi R, Murakami T, Obayashi M, Nakai N, Jaskiewicz J, Fujiwara Y, et al. Clofibric acid stimulates branched-chain amino acid catabolism by three mechanisms. Arch Biochem Biophys. 2002;407:231-40 pubmed
    ..WY-14,643, which, like clofibric acid, is a ligand for the peroxisome-proliferator-activated receptor alpha [PPARalpha], does not directly inhibit ..
  21. Fruchart J, Staels B, Duriez P. The role of fibric acids in atherosclerosis. Curr Atheroscler Rep. 2001;3:83-92 pubmed
    ..Further clinical studies are necessary to investigate if fibric acids decrease cardiovascular mortality in type 2 diabetes and in primary prevention of hypertriglyceridemia and hypolipidemia...
  22. Bakke I, Sandvik A, Waldum H. Octreotide inhibits the enterochromaffin-like cell but not peroxisome proliferator-induced hypergastrinemia. J Mol Endocrinol. 2000;25:109-19 pubmed
    ..Ciprofibrate stimulates gastrin cell activity by a mechanism unaffected by octreotide, but octreotide does inhibit basal and gastrin-stimulated ECL cell function and growth...
  23. Liamis G, Kakafika A, Bairaktari E, Miltiadous G, Tsimihodimos V, Goudevenos J, et al. Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia. Curr Med Res Opin. 2002;18:125-8 pubmed
    ..We conclude that the careful administration of small doses of atorvastatin in patients with mixed dyslipidemia receiving fibrates is associated with a significant amelioration of lipid abnormalities...
  24. Weigel S, Kuhlmann J, Hühnerfuss H. Drugs and personal care products as ubiquitous pollutants: occurrence and distribution of clofibric acid, caffeine and DEET in the North Sea. Sci Total Environ. 2002;295:131-41 pubmed
    ..The method was applied to the screening of samples from different North Sea areas for clofibric acid, diclofenac, ibuprofen, ketoprofen, propyphenazone, caffeine and N,N-diethyl-3-toluamide (DEET)...
  25. Zwiener C, Frimmel F. Short-term tests with a pilot sewage plant and biofilm reactors for the biological degradation of the pharmaceutical compounds clofibric acid, ibuprofen, and diclofenac. Sci Total Environ. 2003;309:201-11 pubmed
    The biodegradation of three active compounds of pharmaceuticals clofibric acid, ibuprofen, and diclofenac was investigated in short-term tests with a pilot sewage plant (PSP) and biofilm reactors (BFR, oxic and anoxic) as model systems ..
  26. Becuwe P, Bianchi A, Keller J, Dauca M. Effects of the peroxisome proliferator clofibric acid on superoxide dismutase expression in the human HepG2 hepatoma cell line. Biochem Pharmacol. 1999;58:1025-33 pubmed
    We examined the effects of clofibric acid, a peroxisome proliferator, on the production of superoxide radicals, on the levels of malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), and on the expression of superoxide dismutases (SODs) in ..
  27. Yadetie F, Laegreid A, Bakke I, Kusnierczyk W, Komorowski J, Waldum H, et al. Liver gene expression in rats in response to the peroxisome proliferator-activated receptor-alpha agonist ciprofibrate. Physiol Genomics. 2003;15:9-19 pubmed
  28. Eacho P, Lanier T, Brodhecker C. Hepatocellular DNA synthesis in rats given peroxisome proliferating agents: comparison of WY-14,643 to clofibric acid, nafenopin and LY171883. Carcinogenesis. 1991;12:1557-61 pubmed
    ..In these studies, WY-14,643 was compared to clofibric acid, nafenopin and LY171883 given to rats in the diet for up to 30 days...
  29. Santos T, Rocha J, Barcelo D. Determination of rice herbicides, their transformation products and clofibric acid using on-line solid-phase extraction followed by liquid chromatography with diode array and atmospheric pressure chemical ionization mass spectrometric detection. J Chromatogr A. 2000;879:3-12 pubmed
    ..During the 3-month monitoring of the herbicides, 8-hydroxybentazone and 4-chloro-2-methylphenoxyacetic acid were successively found in those samples...
  30. Ferrari B, Paxeus N, Lo Giudice R, Pollio A, Garric J. Ecotoxicological impact of pharmaceuticals found in treated wastewaters: study of carbamazepine, clofibric acid, and diclofenac. Ecotoxicol Environ Saf. 2003;55:359-70 pubmed
    ..occurrence in sewage treatment plant (STP) effluents and ecotoxicity of the pharmaceuticals carbamazepine, clofibric acid, and diclofenac were investigated...
  31. Ghaoui R, Sallustio B, Burcham P, Fontaine F. UDP-glucuronosyltransferase-dependent bioactivation of clofibric acid to a DNA-damaging intermediate in mouse hepatocytes. Chem Biol Interact. 2003;145:201-11 pubmed
    ..Whether acyl glucuronides also attack nuclear DNA is unknown, although the acyl glucuronide formed from clofibric acid was recently found to decrease the transfection efficiency of phage DNA and generate strand breaks in plasmid ..
  32. Winkler M, Lawrence J, Neu T. Selective degradation of ibuprofen and clofibric acid in two model river biofilm systems. Water Res. 2001;35:3197-205 pubmed
    A field survey indicated that the Elbe and Saale Rivers were contaminated with both clofibric acid and ibuprofen. In Elbe River water we could detect the metabolite hydroxy-ibuprofen...
  33. Yu X, Odle J, Drackley J. Differential induction of peroxisomal beta-oxidation enzymes by clofibric acid and aspirin in piglet tissues. Am J Physiol Regul Integr Comp Physiol. 2001;281:R1553-61 pubmed
    ..5% clofibric acid (CA) or 1% aspirin for 14 days. CA increased ratios of liver weight to body weight (P < 0...
  34. Ikemoto T, Endo M. Properties of Ca(2+) release induced by clofibric acid from the sarcoplasmic reticulum of mouse skeletal muscle fibres. Br J Pharmacol. 2001;134:719-28 pubmed
    1. To characterize the effect of clofibric acid (Clof) on the Ca(2+) release mechanism in the sarcoplasmic reticulum (SR) of skeletal muscle, we analysed the properties of Clof-induced Ca(2+) release under various conditions using ..
  35. Pusch M, Liantonio A, Bertorello L, Accardi A, De Luca A, Pierno S, et al. Pharmacological characterization of chloride channels belonging to the ClC family by the use of chiral clofibric acid derivatives. Mol Pharmacol. 2000;58:498-507 pubmed
    ..No effects were observed on ClC-5 that shows less than 30% homology with ClC-1. Thus, CPP-like compounds may be useful both to gain insight into biophysical properties of ClC-1 and for searching tissue-specific therapeutic agents...
  36. Wierzbicki A. Fibrates: no ACCORD on their use in the treatment of dyslipidaemia. Curr Opin Lipidol. 2010;21:352-8 pubmed publisher
    ..New data have emerged over the last few years about the role of fibrates in treatment of microvascular and macrovascular disease...
  37. Razavi B, Song W, Cooper W, Greaves J, Jeong J. Free-radical-induced oxidative and reductive degradation of fibrate pharmaceuticals: kinetic studies and degradation mechanisms. J Phys Chem A. 2009;113:1287-94 pubmed publisher
    ..study reports the absolute bimolecular reaction rate constants for three pharmaceutical compounds (fibrates), clofibric acid, bezafibrate, and gemfibrozil, with the hydroxyl radical (*OH) and hydrated electron (e(-)(aq))...
  38. Tenenbaum A, Fisman E, Motro M, Adler Y. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?. Adv Cardiol. 2008;45:127-53 pubmed publisher
  39. Giampietro L, D angelo A, Giancristofaro A, Ammazzalorso A, De Filippis B, Di Matteo M, et al. Effect of stilbene and chalcone scaffolds incorporation in clofibric acid on PPAR? agonistic activity. Med Chem. 2014;10:59-65 pubmed
    ..and efficacious compounds for the treatment of metabolic disorders, new compounds based on a combination of clofibric acid, the active metabolite of clofibrate, and trans-stilbene, chalcone, and other lipophilic groups were ..
  40. Heike Z, Gudrun U, Frank R, Vetter H, Walger P. Multiple benign symmetric lipomatosis--a differential diagnosis of obesity: is there a rationale for fibrate treatment?. Obes Surg. 2008;18:240-2 pubmed publisher
    ..Fibrates, peroxisome proliferator-activated receptor alpha agonists, are pleiotropic hypolipidemic drugs and might have worked by suppression of protein expressions involved in the architecture of BAT keeping it in a quiescent state...
  41. Nieland T, Shaw J, Jaipuri F, Maliga Z, Duffner J, Koehler A, et al. Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI. J Lipid Res. 2007;48:1832-45 pubmed
    ..HDL376 and other inhibitors may help elucidate SR-BI function in diverse mammalian models and determine the therapeutic potential of SR-BI-directed pharmaceuticals...
  42. Elijovich F. 20-HETE and salt-sensitivity of blood pressure a novel emerging concept. Am J Hypertens. 2006;19:1181-2 pubmed
  43. Meyers C, Kashyap M. Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies. Curr Opin Cardiol. 2005;20:307-12 pubmed
  44. Hausenloy D, Yellon D. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Postgrad Med J. 2008;84:590-8 pubmed publisher
    ..Therefore, raising HDL-C represents an important strategy for reducing residual cardiovascular risk in patients already optimally treated with statins, and should lead to further improvements in clinical outcomes in these patient groups...
  45. Knopp R, Paramsothy P, Atkinson B, Dowdy A. Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk. Am J Cardiol. 2008;101:48B-57B pubmed publisher
    ..In conclusion, 5 lines of evidence justify comprehensive diet and drug treatment for combined hyperlipidemia and, at lesser LDL elevations, the atherogenic dyslipidemias of obesity, diabetes mellitus, and the metabolic syndrome...
  46. Avis H, Vissers M, Wijburg F, Kastelein J, Hutten B. The use of lipid-lowering drug therapy in children and adolescents. Curr Opin Investig Drugs. 2009;10:224-31 pubmed
    ..Nevertheless, more studies are needed to confirm the lifelong benefit of lipid-lowering therapy initiated in childhood...
  47. Merkel M. [Diabetic dyslipoproteinemia: beyond LDL]. Dtsch Med Wochenschr. 2009;134:1067-73 pubmed publisher
    ..Thus, statin therapy to decrease LDL cholesterol to target is the essential treatment for diabetic dyslipidemia to reduce cardiovascular risk. Other lipid lowering drugs can be added optionally...
  48. Denke M. Coadministration of multidrug therapy to achieve lipid goals. J Am Osteopath Assoc. 2004;104:S17-22 pubmed
    ..The coadministration of low doses of these agents has been proved to be as effective as high-dose statin therapy in reducing LDL-C levels and assisting patients achieve their treatment goals...
  49. Toyama T, Kudo N, Mitsumoto A, Kawashima Y. Regulation of palmitoyl-CoA chain elongation by clofibric acid in the liver of Zucker fa/fa rats. Lipids. 2005;40:463-70 pubmed
    The regulation of palmitoyl-CoA chain elongation (PCE) by clofibric acid [2-(4-chlorophenoxy)-2-methylpropionic acid] was investigated in comparison with stearoyl-CoA desaturase (SCD) in the liver of obese Zucker fa/fa rats...
  50. Cunard R. The potential use of PPARalpha agonists as immunosuppressive agents. Curr Opin Investig Drugs. 2005;6:467-72 pubmed
    ..This review focuses on the use of fibrates in inflammatory disease models. It also describes proposed mechanisms of action of PPARalpha ligands and discusses the potential use of these medications as immunosuppressive agents...
  51. Yamazaki T, Wakabayashi M, Ikeda E, Tanaka S, Sakamoto T, Mitsumoto A, et al. Induction of 1-acylglycerophosphocholine acyltransferase genes by fibrates in the liver of rats. Biol Pharm Bull. 2012;35:1509-15 pubmed
    The effect of fibrates (clofibric acid, bezafibrate and fenofibrate) on the gene expression and activity of 1-acylglycerophosphocholine acyltransferase (LPCAT) was investigated. The administration of 0...
  52. Zhang D, Gersberg R, Hua T, Zhu J, Ng W, Tan S. Assessment of plant-driven uptake and translocation of clofibric acid by Scirpus validus. Environ Sci Pollut Res Int. 2013;20:4612-20 pubmed publisher
    ..The overall objective of this study was to evaluate the uptake and translocation of clofibric acid (CA) by the macrophyte Scirpus validus growing hydroponically...
  53. Miyamoto K, Hoshino T, Yamashita M, Ueda J. Automorphosis of etiolated pea seedlings in space is simulated by a three-dimensional clinostat and the application of inhibitors of auxin polar transport. Physiol Plant. 2005;123:467-74 pubmed